Patients with systemic lupus erythematosus (SLE) have altered incidences of certain malignancies as compared with the general population. This review summarizes the recent literature on risk of malignancy in SLE and proposed mechanisms for these altered susceptibilities.
INTRODUCTION
Multiple studies have assessed the overall rates of malignancy in patients with SLE versus general population controls. Bernatsky et al. [1] , in a large multinational study involving 16 409 patients primarily from the Systemic Lupus International Collaborating Clinics, the Canadian Network for Improved Outcomes in Systemic Lupus, and other international collaborators, demonstrated a slightly increased overall risk of malignancy in patients with systemic lupus erythematosus (SLE) as compared with controls [standardized incidence ratio (SIR) 1.14, 95% confidence interval (CI), 1.05, 1.23] . This trend has been demonstrated in multiple other cohorts, including a Taiwanese cohort of 11 763 patients [2] , a UK cohort of 595 patients [3] , and a Danish cohort of 576 patients [4] . Most recently, a meta-analysis by Ni et al. [5 & ] corroborated these data by demonstrating a pooled increased incidence of malignancy in SLE (pooled SIR 1.16, 95% CI, 1.14, 1.21).
Thomas et al. [6] in a retrospective cohort study found that the standardized mortality ratio (SMR) from malignancy was quite low in patients with SLE (SMR 0.40, 95% CI, 0.34, 0.48). Similarly, Yurkovich et al. [7] in their meta-analysis reported that the SMR for malignancy was not increased in patients with SLE (SMR 1.16, 95% CI, 0.57, 2.35). Thomas et al. suggest that this lower SMR may be explained by an increased SMR for cardiovascular and infectious diseases at a younger age in patients with SLE. This may prevent a significant proportion of the SLE population from reaching an age wherein malignancy has a greater impact on mortality [6] .
HEMATOLOGIC MALIGNANCIES
Bernatsky et al. [1] has demonstrated an increased risk for all hematologic malignancies in SLE (SIR 3.02, 95% CI, 2.48, 3.63), particularly for non-Hodgkin's lymphoma (NHL) (SIR 4.39, 95% CI, 3.46, 5.49) [8] .
The most common form of nonlymphoma malignancy in this international cohort was of the myeloid type (specifically myelodysplastic syndromes and acute myeloid leukemias) [8] . A recent study by Fallah et al. [9 && ] linking 12 207 patients with SLE identified from the Swedish Hospital Discharge Registry with the Swedish Cancer Registry found an increased risk of NHL (SIR 4.4, 95% CI, 3.6, 5.3).
A meta-analysis by Apor et al. [10 & ] demonstrated a heightened risk of all forms of hematologic malignancy in SLE (pooled SIR 2.9, 95% CI, 2.0, 4.4), most notably for NHL (pooled SIR 5.7, 95% CI, 3.6, 9.1). They demonstrated that these increased incidences were seen across a wide variation of ages, sexes, and geographical populations. Apor et al. [10 & ] also demonstrated an increased risk of Hodgkin's lymphoma (pooled SIR 3.1, 95% CI, 2.1, 4.4), leukemia (pooled SIR 2.3, 95% CI, 1.9, 2.7), and myeloma (pooled SIR 1.5, 95% CI, 1.0, 2.0).
It has been postulated that increased disease activity in SLE may mediate this increased risk of hematologic malignancies. However, a case-cohort study nested within an international cohort of Bernatsky et al. [ Multiple studies have suggested that EBV may play a role in the pathogenesis of SLE and may mediate an increased risk of malignancy. EpsteinBarr viral load, mRNA expression and EBV-directed antibodies have all been shown to be elevated in SLE [12] . Rasmussen et al. [13] recently demonstrated that immunoglobulin M (IgM), IgG, and IgA levels against EBV early antigen/diffuse were significantly higher in patients with SLE, which they suggest may be related to aberrant control of EBV reactivation in these patients. Hanlon et al. [14] , in a recent metaanalysis including 25 case-control studies demonstrated a higher prevalence of antiviral capsid antigen (anti-VCA) IgG [odds ratio (OR) 2.08, 95% CI, 1.15, 3.76] in patients with SLE. Anti-VCA IgG is a marker of prior EBV infection that develops a few months after exposure to EBV and lasts for life [14] . EBV has also been shown to play an important role in the pathogenesis of various hematologic malignancies, including Burkitt's lymphoma, Hodgkin's lymphoma, and diffuse large B-cell lymphoma in immunosuppressed patients. Based on this understanding, recent successful adjuvant therapies for Hodgkin's lymphoma and NHL have been developed, which use cytotoxic T cells targeted against latent membrane proteins of EBV to induce remission [15] . Capone et al. [16 && ] recently demonstrated an Epstein-Barr nuclear antigen peptide sequence that is intrinsic to the EBV viral genome, but which is not present in the human host. They suggest that creating a vaccine based on this peptide could potentially decrease the risk of autoimmune diseases such as SLE as well as EBV-associated malignancies [16 && ]. A review by Yao et al. [17] suggests there may be a relationship between increased interleukin-6 activity in SLE and the increased risk of hematologic malignancies. Interleukin-6 is a cytokine released from monocytes and macrophages during inflammatory states that leads to increased growth and differentiation with decreased apoptosis in neutrophils, monocytes, and T and B cells [18] . Interleukin-6 receptors have been demonstrated on mantle cell lymphoma cells, some of which also secrete interleukin-6 [19] . In-vitro inhibition of interleukin-6 in
KEY POINTS
SLE is associated with an overall increased risk of malignancy, particularly NHL, lung, liver, vulvar/ vaginal, and thyroid, and a decreased risk of breast and prostate cancer.
The increased risk of NHL is likely related to multiple mechanisms, including increased viral reactivation, and upregulation of cytokines such as BAFF/APRIL and interleukin-6.
The decreased risk of breast and prostate cancer may be related to anti-dsDNA antibodies that increase the susceptibility of malignant cells to apoptosis and chemotherapeutic agents.
There are no guidelines on cancer screening specifically for patients with SLE, and these patients should adhere to general population screening recommendations, particularly for cervical cancer.
mantle cell lymphomas has led to inhibition of growth and spontaneous apoptosis of malignant cells as well as increased responsiveness to chemotherapy [19] . A recent study by Miaer-Moore et al. [20 && ] has shown that interleukin-6 activity is associated with many of the disease manifestations seen in SLE. Interleukin-6-deficient mice had less nephritis, lung disease, and autoantibody production, and notably decreased numbers of germinal B cells and IgG-producing plasma cells in the spleen [20 && ]. Inhibition of interleukin-6 via tocilizumab, a monoclonal antibody against the interleukin-6 receptor, in patients with SLE resulted in decreased lymphocyte activation and normalization of B-cell and T-cell homeostasis [21] . Thus, it could be speculated that increased interleukin-6 activity may underlie some of the increased risk of hematologic malignancies in SLE.
B-cell activating factor (BAFF, also known as Blymphocyte stimulator -BLyS) and a proliferationinducing ligand (APRIL) are two cytokines within the tumor necrosis factor family that are essential to B-cell survival and proliferation. Overexpression of BAFF has been demonstrated in patients with SLE [22] and BAFF mRNA levels have been shown to correlate with global disease activity in patients with SLE as well as proteinuria and elevated anti-dsDNA and ESR (erythrocyte sedimentation rate) [23] . The APRIL and BAFF axis may also play a role in the increased risk of hematologic malignancies in SLE. These cytokines act on the BAFF-receptor3, transmembrane activator and cyclophilin ligand interactor (TACI), and B-cell maturation antigen. Belimumab, a monoclonal antibody that inhibits circulating BAFF, was approved relatively recently for the treatment of SLE after phase III trials demonstrated improvements primarily in the cutaneous and musculoskeletal manifestations of SLE [24, 25] . Research is also currently underway evaluating the utility of novel therapeutics targeting the BAFF/ APRIL pathways and their receptors in treating hematologic malignancies. A fusion protein Bax345/ BAFF has been shown by Lyu et al. [26 && ] to induce apoptosis when delivered to malignant B cells.
Overexpression of APRIL has been observed in patients with SLE that have developed diffuse large B-cell lymphomas [27] . Hoffman et al. [28 & ] have recently demonstrated that soluble TACI (sTACI), a soluble receptor for APRIL and BAFF, is elevated in patients with SLE. Lascano et al. [29] demonstrated increased malignant B-cell survival in chronic lymphocytic leukemia when APRIL binds to sTACI. As such, the fusion protein against TACI and B-cell maturation antigen receptors, atacicept, is currently being studied for the treatment of both SLE and various hematologic malignancies [30, 31] .
Atacicept has also been shown to prevent B-cell expansion in mouse models of chronic lymphocytic leukemia [32] , and is currently being evaluated in phase I trials for the treatment of chronic lymphocytic leukemia, NHL, and multiple myeloma [30] . [33] . The SMR was also increased for small cell lung cancer in patients with SLE (SMR 2.69, 95% CI, 2.11, 3.38), suggesting increased mortality in patients with SLE with this form of lung cancer [33] .
LUNG MALIGNANCIES
Ni et al. [5 & ] suggest that there may be a link between the increased rate of lung cancer and the increased rates of smoking in patients with SLE as well as increased disease activity associated with smoking in SLE. Smoking has also been associated with the development of SLE [34] .
There may also be increased rates of lung cancer in patients with pulmonary manifestations of SLE. Hemminki et al. [33] assessed multiple forms of autoimmune disease and noted that only diseases with lung manifestations were associated with an increased risk of lung malignancy. They postulated that this increased incidence is related to local inflammation and associated oxidative lesions [33] . However, there have been no studies that clearly associate the development of lung malignancy in patients with SLE with prior pulmonary involvement of the disease.
As described above, interleukin-6 activity has been implicated in the pathogenesis and activity of SLE [17] . Interleukin-6 has been particularly associated with lung manifestations in SLE [20 && ]. A recent study by Kim et al. [35] demonstrated that the anti-interleukin-6R-targeted antibody, tocilizumab, was effective in inducing apoptosis in nonsmall cell lung cancer cell lines. Preliminary studies indicate tocilizumab may also be efficacious in treating SLE [36] . Based on these data, it could be speculated that increased interleukin-6 activity could represent a common mechanism between SLE activity and lung cancer development. 
HEPATOBILIARY MALIGNANCIES

BREAST CANCER
It has been demonstrated that the rates of hormoneassociated malignancies may be decreased in patients with SLE [1, 3, 4] . Specifically, Bernatsky et al. [1] found the rate of breast cancer in the SLE population to be substantially decreased (SIR 0.76, 95% CI, 0.69, 0.85) [39] .
Recent data have suggested that SLE autoantibodies may contribute to the decreased risk of certain hormone-sensitive malignancies. A cellpenetrating, lupus-related, anti-DNA antibody was shown to inhibit DNA repair, and was thus toxic to cancer cells with intrinsic defects in DNA repair [40] . Triple-negative (i.e. breast cancers that do not express estrogen, progesterone, or human epidermal growth factor 2 receptors) and BRCA2-mutated breast cancers harbor defects in DNA repair. It is possible that suppression of the emergence of triplenegative and BRCA2-mutated breast cancers by lupus anti-DNA antibodies may be partially responsible for the lower-than-expected rates of breast cancer in women with SLE. This line of reasoning is supported by a trend for decreased ductal carcinoma, which is predominantly triple-negative, in a cohort of Bernatsky et al. [41] ] have demonstrated that patients with SLE with ENA (extractable nuclear antigen) positivity express lower levels of HSP-27 in their serum. Grzegrzolka et al. [44] have shown that 92% of cases of invasive ductal carcinoma express HSP-27. Further, they showed that increased HSP-27 levels correlated with higher breast cancer grade and human epidermal growth factor 2 positivity [44] . Several studies have also demonstrated that suppression of HSP-27 in breast cancer causes dormancy [45] and increases susceptibility to treatment [46] . Thus, it could be speculated that if patients with SLE have decreased levels of HSP-27, they may have less propensity to develop aggressive invasive ductal carcinomas. There have been conflicting reports regarding the incidence of cervical cancer in patients with SLE. This may be related to the relatively low rate of cervical cancers in general, as a result of improved cervical cancer screening. Nonetheless, Dreyer et al. [4] demonstrated that the rate of cervical dysplasia/ carcinoma was significantly increased (SIR 1.8, 95% CI, 1.2, 2.7). This was supported by a recent metaanalysis by Zard et al. [47 & ], which demonstrated a substantially increased risk of high-grade squamous intraepithelial lesions in SLE (pooled OR8.66, 95% CI, 3.75, 20.00).
VAGINAL, VULVAR, AND CERVICAL CANCERS
Dreyer et al. [4] suggested that the increased risk of vaginal/vulvar and cervical malignancies may be related to impaired HPV clearance in SLE. Zard et al. [47 & ] also supported increased HPV activity as a potential disease for the increased risk of cervical dysplasia in SLE. It has been demonstrated in a Brazilian cross-sectional analysis that the rates of HPV infection are increased in patients with SLE compared with controls (OR 7.2, 95% CI, 2.9, 17.8) [48] . This study [48] did not show a correlation between higher doses of immunosuppressive treatment and HPV prevalence.
PROSTATE CANCER
There have been varied results regarding the rates of prostate cancer in patients with SLE. Meta-analysis by Ni et al. [5 & ], which includes data from an international cohort of Bernatsky et al., has demonstrated a decreased incidence of prostate cancer (pooled). Recent systematic review of urologic malignancies in SLE by Huang et al. [49 & ] also supported this conclusion. In contrast, a study by Liu et al. [50] of 7613 patients with SLE identified through the Swedish Hospital Discharge Registry demonstrated that the risk of prostate cancer was similar to that of the general population (SIR 1.03, 95% CI, 0.73, 1.41).
HSP-27 has been implicated in prostate cancer progression and metastases [51] and HSP-27 levels have also been shown to be an independent predictor of poor prognosis in prostate cancer [52] . Inhibition of HSP-27 in castrate-resistant prostate cancer has been found to increase apoptosis, inhibit growth of the tumors, and increase survival in mouse models [53] . As noted above, HSP-27 has been demonstrated to be decreased in ENA-positive patients with SLE [43
&&
]. As such, it could be speculated that decreased levels of HSP-27 in patients with SLE may contribute to a decreased incidence of prostate cancer.
BLADDER CANCER
Liu et al. demonstrated through analysis of the Swedish Hospital Discharge Registry that the rate of bladder cancer was significantly increased in the 7624 patients with SLE studied (SIR 2.28, 95% CI, 1.62, 3.12). The relative risk of death from bladder cancer was also increased in SLE as compared with controls (HR 2.13, 95% CI, 1.46, 3.11) [50] . Dreyer et al. [4] corroborated increased bladder cancer rates (SIR 3.6, 95% CI, 1.4, 9.7) and found that all patients with SLE with bladder cancer in their cohort had received cyclophosphamide. However, metaanalysis by Ni et al. [5 & ] demonstrated that the rate of bladder cancer was not significantly increased in their pooled analysis in patients with SLE compared with controls (pooled SIR 1.78, 95% CI 0.85, 3.72).
THYROID MALIGNANCIES
A recent meta-analysis by Zhang et al. [54 & ] demonstrated an increased incidence of thyroid cancer based on seven international cohort studies (pooled SIR 2.22, 95% CI, 2.11, 2.34). Antonelli et al. [55] found that 80% of patients with SLE with papillary thyroid cancer had concomitant autoimmune thyroid disease, whereas only 30% of patients with SLE without thyroid malignancy had thyroid autoimmunity. 
IMPLICATIONS FOR CLINICAL PRACTICE
CONCLUSION
It has been well established that there are altered rates of certain malignancies in SLE. Recent studies have not only confirmed increased rates of NHL and lung, hepatobiliary, vulvar/vaginal, and thyroid malignancies, as well as cervical dysplasia, but they have also postulated mechanisms to explain this increased incidence. NHL may be intrinsically related to altered BAFF and APRIL signaling, and interleukin-6 may also play a role in increased rates of NHL and lung malignancies in SLE. Increased incidence of certain malignancies may also be related to increased SLE disease activity within a specific organ, altered viral clearance, and/or specific medication use.
Recent studies have also documented decreased rates of breast and prostate cancer in SLE and speculated on potential underlying mechanisms. Of note, cell-penetrating anti-DNA autoantibodies may play an important role in decreasing the risk of breast cancer in patients with SLE. Cytokine pathways such as those mediated by HSP-27 may also play an important role in decreasing the risk of breast and prostate cancer in SLE.
Despite an apparent decreased risk of breast and prostate cancer, patients with SLE should adhere to general population cancer screening recommendations and they should be particularly vigilant for cervical dysplasia.
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